

Prevention and the Agency for Toxic Substances and Disease Registry.

**Catherine Ramadei,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2015–32014 Filed 12–21–15; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review**

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity (FOA) CK16–004, Epicenters for the Prevention of Healthcare-Associated Infections, Antimicrobial Resistance, and Adverse Events.

*Time and Date:* 10:00 a.m.–5:00 p.m., March 2–3, 2016 (Closed).

*Place:* Teleconference.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

*Matters for Discussion:* The meeting will include the initial review, discussion, and evaluation of applications received in response to “Epicenters for the Prevention of Healthcare-Associated Infections, Antimicrobial Resistance, and Adverse Events”, FOA CK16–004.

*Contact Person For More Information:* Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE., Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 718–8833. The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

**Catherine Ramadei,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2015–32018 Filed 12–21–15; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

[30Day–16–1006]

**Agency Forms Undergoing Paperwork Reduction Act Review**

The Centers for Disease Control and Prevention (CDC) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The notice for the proposed information collection is published to obtain comments from the public and affected agencies.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address any of the following: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570 or send an email to [omb@cdc.gov](mailto:omb@cdc.gov). Written comments and/or suggestions regarding the items contained in this notice should be directed to the Attention: CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395–5806. Written

comments should be received within 30 days of this notice.

**Proposed Project**

CDC Work@Health® Program: Phase 2 Training and Technical Assistance Evaluation (OMB No. 0920–1006, exp. date 1/31/2016)—Revision—National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC).

*Background and Brief Description*

The Centers for Disease Control and Prevention (CDC) is continuing to make available the Work@Health® Program, a comprehensive worksite health promotion training program, to support employers' efforts to create healthy work environments and provide employees with opportunities to make healthy lifestyle choices. The Work@Health® Program will train and support small, mid-size, and large employers with three primary goals: (1) Increase understanding of the training needs of employers and the best way to deliver skill-based training to them; (2) Increase employers' level of knowledge and awareness of worksite health program concepts and principles; and (3) Increase the number of science-based worksite health programs, policies, and practices in place in participating employers' worksites resulting in opportunities for employees to participate in them.

CDC is requesting OMB approval to continue Phase 2 information collection with new cohorts of respondents in 2016–2019. Phase 2 procedures were informed by a needs assessment and pilot test that were conducted in fall 2013 (“CDC Work@Health® Program: Phase 1,” OMB No. 0920–0989, exp. 9/30/2014) as well as first year results. CDC will offer training in four models (formats): (1) A “Hands-on” instructor-led workshop model (T1), (2) a self-paced “Online” model (T2), (3) a combination or “Blended” model (T3), and (4) a “Train-the-Trainer” model (T4) designed to prepare qualified individuals to train employers through the Hands-on, Online, or Blended models.

To evaluate the training, information will be collected from approximately 480 employers and approximately 120 individuals who are interested in becoming trained/certified instructors for the Work@Health® Program. In addition, information will be collected from approximately 600 participant who receive training delivered by the trained/certified instructors. Respondents will include employers/employees, trainees who participate in

the four training models, and training and technical assistance instructors, coaches and subject matter experts. CDC will use the information collected to evaluate the effectiveness of the Work@Health® Program in terms of (1) increasing employer’s knowledge and awareness of worksite health concepts, principles, and resources, and

(2) increasing the number of science-based worksite health programs, policies and practices in place at participating employers’ worksites. The information will also be used to continue to identify and improve the best way(s) to deliver skill-based training and technical support to

employers in the area of worksite health.

OMB approval is requested for three years. Participation in Work@Health® is voluntary and there are no costs to participants other than their time. The total estimated annualized burden hours are 1,047.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hrs.)	
Interested Employer .....	Employer Application Form .....	400	1	20/60	
	Employers Participating in Work@Health.	CDC Worksite Health Scorecard .....	320	1	0.5
		Organizational Assessment .....	320	1	15/60
		Employer Follow-up Survey .....	160	1	15/60
		Case Study Interviews with Senior Leadership .....	2	1	1
		Case Study Interviews with Employees .....	4	1	1
Trainees Participating in the Work@Health Program (Hands-on, Online, Blended models).	Trainee KAB Survey .....	640	1	20/60	
	Trainee Reaction Survey—Hands-On Model .....	100	1	15/60	
	Trainee Reaction Survey—Online Model .....	120	1	15/60	
	Trainee Reaction Survey—Blended Model .....	100	1	15/60	
	Trainee Technical Assistance Survey .....	640	1	15/60	
	Case Study Interviews with Selected Trainees .....	10	1	1	
	Trainee Focus Group Discussion Guide .....	7	1	1.5	
	Interested Train-the-Trainer Participants.	Train-the-Trainer Application Form .....	80	1	0.5
Trainees Participating in the Work@Health Program (Train-the-Trainer model).	Train-the-Trainer Participant Survey .....	80	1	20/60	
	Trainee Reaction Survey—Train-the-Trainer Model .....	40	1	15/60	
	Train-the-Trainer Trainee Technical Assistance Survey .....	80	1	15/60	
Trainees participating in the Work@Health Program Wave 2.	Wave 2 Trainee Reaction Survey .....	200	1	15/60	
	Work@Health Instructors/Coaches.	Instructor/Coach Group Discussion Guide .....	7	1	0.5

**Leroy A. Richardson,**  
*Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.*

[FR Doc. 2015–32139 Filed 12–21–15; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review**

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity Announcement (FOA) DP 16–001, Pregnancy Risk Assessment Monitoring System (PRAMS).

Time and Date: 11:00 a.m.–6:00 p.m., EST, Panel C, February 3, 2016 (Closed)  
 Place: Teleconference  
 Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to “FOA DP16–001, Panel C, Pregnancy Risk Assessment Monitoring System (PRAMS)”.

Contact Person for More Information: Jayalakshmi Raman Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta, Georgia 30341, Telephone: (770) 488–6511, [kva5@cdc.gov](mailto:kva5@cdc.gov).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the

Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Catherine Ramadei,**  
*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2015–32017 Filed 12–21–15; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Advisory Committee on Breast Cancer in Young Women (ACBCYW)**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

Times and Dates: 9:30 a.m.–4:00 p.m. EST, January 28, 2016; 9:30 a.m.–3:00 p.m. EST, January 29, 2016.